首页> 美国卫生研究院文献>World Journal of Gastroenterology >Diagnostic value of PIVKA-II and alpha-fetoprotein in hepatitis B virus-associated hepatocellular carcinoma
【2h】

Diagnostic value of PIVKA-II and alpha-fetoprotein in hepatitis B virus-associated hepatocellular carcinoma

机译:PIVKA-II和甲胎蛋白对乙型肝炎病毒相关肝细胞癌的诊断价值

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

AIM: To determine the cutoff values and to compare the diagnostic role of alpha-fetoprotein (AFP) and prothrombin induced by vitamin K absence-II (PIVKA-II) in chronic hepatitis B (CHB).METHODS: A total of 1255 patients with CHB, including 157 patients with hepatocellular carcinoma (HCC), 879 with non-cirrhotic CHB and 219 with cirrhosis without HCC, were retrospectively enrolled. The areas under the receiver operating characteristic (AUROC) curves of PIVKA-II, AFP and their combination were calculated and compared.RESULTS: The optimal cutoff values for PIVKA-II and AFP were 40 mAU/mL and 10 ng/mL, respectively, for the differentiation of HCC from nonmalignant CHB. The sensitivity and specificity were 73.9% and 89.7%, respectively, for PIVKA-II and 67.5% and 90.3% for AFP, respectively. The AUROC curves of both PIVKA-II and AFP were not significantly different (0.854 vs 0.853, P = 0.965) for the differentiation of HCC from nonmalignant CHB, whereas the AUROC of PIVKA-II was significantly better than that of AFP in patients with cirrhosis (0.870 vs 0.812, P = 0.042). When PIVKA-II and AFP were combined, the diagnostic power improved significantly compared to either AFP or PIVKA-II alone for the differentiation of HCC from nonmalignant CHB (P < 0.05), especially when cirrhosis was present (P < 0.05).CONCLUSION: Serum PIVKA-II might be a better tumor marker than AFP, and its combination with AFP may enhance the early detection of HCC in patients with CHB.
机译:目的:确定临界值并比较维生素K缺乏II(PIVKA-II)诱导的甲型甲胎蛋白(AFP)和凝血酶原在慢性乙型肝炎(CHB)中的诊断作用。方法:总共1255例患者回顾性分析了包括157例肝细胞癌(HCC),879例非肝硬化性CHB和219例无HCC肝硬化的CHB。计算并比较了PIVKA-II,AFP及其组合的受体工作特征曲线下的面积。结果:PIVKA-II和AFP的最佳临界值分别为40 mAU / mL和10 ng / mL。用于区分HCC与非恶性CHB。 PIVKA-II的敏感性和特异性分别为73.9%和89.7%,AFP的敏感性和特异性分别为67.5%和90.3%。 PIVKA-II和AFP的AUROC曲线在肝癌与非恶性CHB的分化方面无显着差异(0.854 vs 0.853,P = 0.965),而肝硬化患者中PIVKA-II的AUROC明显优于AFP (0.870 vs 0.812,P = 0.042)。当将PIVKA-II和AFP合并使用时,与单独使用AFP或PIVKA-II相比,对于将HCC与非恶性CHB进行区分的诊断能力显着提高(P <0.05),特别是在存在肝硬化的情况下(P <0.05)。血清PIVKA-II可能是比AFP更好的肿瘤标志物,将其与AFP联合使用可以增强CHB患者早期肝癌的检测。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号